Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Renal Dialysis | 72 | 2021 | 279 | 9.290 |
Why?
|
Kidney Failure, Chronic | 68 | 2021 | 541 | 7.570 |
Why?
|
Hemodialysis, Home | 12 | 2020 | 13 | 3.450 |
Why?
|
Antihypertensive Agents | 18 | 2022 | 352 | 3.270 |
Why?
|
Hypertension | 29 | 2022 | 959 | 3.230 |
Why?
|
Blood Pressure | 26 | 2022 | 845 | 3.030 |
Why?
|
Renal Insufficiency, Chronic | 15 | 2020 | 288 | 2.280 |
Why?
|
Peritoneal Dialysis | 7 | 2020 | 26 | 2.060 |
Why?
|
Practice Guidelines as Topic | 15 | 2020 | 407 | 2.000 |
Why?
|
Kidney Diseases | 11 | 2016 | 249 | 1.910 |
Why?
|
Nephrology | 6 | 2019 | 33 | 1.800 |
Why?
|
Humans | 143 | 2022 | 31974 | 1.520 |
Why?
|
Glomerular Filtration Rate | 14 | 2020 | 306 | 1.380 |
Why?
|
Middle Aged | 93 | 2021 | 11804 | 1.340 |
Why?
|
Nutritional Status | 10 | 2013 | 75 | 1.320 |
Why?
|
Aged | 73 | 2021 | 10294 | 1.150 |
Why?
|
Female | 98 | 2021 | 19939 | 1.150 |
Why?
|
Male | 98 | 2021 | 19143 | 1.140 |
Why?
|
Hospitalization | 11 | 2021 | 469 | 1.050 |
Why?
|
Cardiovascular Diseases | 16 | 2022 | 1127 | 1.050 |
Why?
|
Blood Pressure Determination | 7 | 2020 | 100 | 0.980 |
Why?
|
Kidney | 8 | 2018 | 518 | 0.950 |
Why?
|
United States | 32 | 2020 | 3931 | 0.910 |
Why?
|
Treatment Outcome | 29 | 2021 | 3302 | 0.900 |
Why?
|
Hypertrophy, Left Ventricular | 8 | 2021 | 120 | 0.880 |
Why?
|
Adult | 52 | 2022 | 9339 | 0.830 |
Why?
|
Peritoneal Dialysis, Continuous Ambulatory | 3 | 2020 | 3 | 0.820 |
Why?
|
Risk Factors | 30 | 2022 | 3867 | 0.800 |
Why?
|
Apolipoproteins | 8 | 2016 | 200 | 0.780 |
Why?
|
Renal Insufficiency | 2 | 2020 | 58 | 0.770 |
Why?
|
Lipoproteins, HDL | 8 | 2016 | 251 | 0.770 |
Why?
|
Disease Management | 2 | 2014 | 126 | 0.750 |
Why?
|
Time Factors | 24 | 2021 | 2147 | 0.700 |
Why?
|
Patient Education as Topic | 3 | 2020 | 271 | 0.690 |
Why?
|
Randomized Controlled Trials as Topic | 15 | 2020 | 510 | 0.670 |
Why?
|
Societies, Medical | 2 | 2020 | 163 | 0.660 |
Why?
|
Kidney Cortex Necrosis | 1 | 2018 | 2 | 0.660 |
Why?
|
Thrombotic Microangiopathies | 1 | 2018 | 8 | 0.650 |
Why?
|
Health Services Accessibility | 2 | 2018 | 241 | 0.640 |
Why?
|
Serum Albumin | 11 | 2013 | 54 | 0.640 |
Why?
|
Foundations | 2 | 2016 | 8 | 0.620 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2020 | 353 | 0.610 |
Why?
|
Urea | 11 | 2013 | 37 | 0.610 |
Why?
|
Quality of Life | 11 | 2020 | 946 | 0.580 |
Why?
|
Creatinine | 10 | 2021 | 195 | 0.570 |
Why?
|
Cause of Death | 8 | 2017 | 236 | 0.570 |
Why?
|
Proportional Hazards Models | 15 | 2019 | 753 | 0.540 |
Why?
|
Catheterization, Central Venous | 4 | 2008 | 62 | 0.520 |
Why?
|
Hemodialysis Solutions | 3 | 2016 | 4 | 0.510 |
Why?
|
Risk Assessment | 13 | 2020 | 1422 | 0.490 |
Why?
|
Program Development | 2 | 2020 | 96 | 0.490 |
Why?
|
Ergocalciferols | 1 | 2014 | 3 | 0.490 |
Why?
|
Anticoagulants | 2 | 2017 | 123 | 0.480 |
Why?
|
Cholecalciferol | 1 | 2014 | 21 | 0.480 |
Why?
|
Energy Intake | 6 | 2013 | 128 | 0.480 |
Why?
|
Aged, 80 and over | 19 | 2021 | 3988 | 0.470 |
Why?
|
Clinical Trials as Topic | 4 | 2020 | 301 | 0.450 |
Why?
|
Kidney Transplantation | 6 | 2020 | 517 | 0.450 |
Why?
|
Heart Failure | 5 | 2021 | 634 | 0.440 |
Why?
|
African Americans | 12 | 2016 | 1425 | 0.430 |
Why?
|
Vitamin D | 1 | 2014 | 184 | 0.430 |
Why?
|
Quality Assurance, Health Care | 3 | 2009 | 72 | 0.410 |
Why?
|
Medicare | 5 | 2020 | 206 | 0.410 |
Why?
|
Follow-Up Studies | 18 | 2021 | 2265 | 0.410 |
Why?
|
Severity of Illness Index | 7 | 2020 | 881 | 0.400 |
Why?
|
Body Surface Area | 2 | 2008 | 15 | 0.400 |
Why?
|
Prospective Studies | 15 | 2019 | 2278 | 0.390 |
Why?
|
Algorithms | 2 | 2019 | 492 | 0.390 |
Why?
|
Citrates | 1 | 2010 | 5 | 0.380 |
Why?
|
Cystatin C | 3 | 2020 | 31 | 0.370 |
Why?
|
Sleep | 1 | 2011 | 92 | 0.370 |
Why?
|
Albuminuria | 4 | 2020 | 181 | 0.370 |
Why?
|
Consensus | 3 | 2020 | 85 | 0.370 |
Why?
|
Systole | 6 | 2020 | 99 | 0.370 |
Why?
|
Diet | 1 | 2013 | 391 | 0.360 |
Why?
|
Heparin | 1 | 2010 | 74 | 0.360 |
Why?
|
Diabetic Nephropathies | 5 | 2016 | 224 | 0.350 |
Why?
|
Guideline Adherence | 3 | 2013 | 119 | 0.350 |
Why?
|
Kidney Tubules | 2 | 2020 | 26 | 0.340 |
Why?
|
Sodium | 2 | 2021 | 39 | 0.330 |
Why?
|
Body Size | 1 | 2008 | 33 | 0.320 |
Why?
|
Anemia | 6 | 2009 | 58 | 0.320 |
Why?
|
Patient Compliance | 3 | 2019 | 225 | 0.310 |
Why?
|
beta 2-Microglobulin | 3 | 2019 | 6 | 0.310 |
Why?
|
Disease Progression | 6 | 2021 | 593 | 0.310 |
Why?
|
Adolescent | 11 | 2022 | 3537 | 0.300 |
Why?
|
Arteriovenous Shunt, Surgical | 6 | 2013 | 48 | 0.290 |
Why?
|
Survival Analysis | 9 | 2018 | 482 | 0.290 |
Why?
|
Appetite | 5 | 2011 | 22 | 0.290 |
Why?
|
Catheters, Indwelling | 4 | 2010 | 43 | 0.290 |
Why?
|
Health Personnel | 4 | 2020 | 121 | 0.280 |
Why?
|
Health Status Indicators | 1 | 2006 | 73 | 0.270 |
Why?
|
Patients | 2 | 2020 | 46 | 0.270 |
Why?
|
Living Donors | 2 | 2020 | 64 | 0.270 |
Why?
|
Kidney Function Tests | 4 | 2016 | 107 | 0.270 |
Why?
|
Cohort Studies | 9 | 2018 | 1813 | 0.270 |
Why?
|
Dietetics | 1 | 2005 | 4 | 0.260 |
Why?
|
Nutritional Physiological Phenomena | 1 | 2005 | 19 | 0.260 |
Why?
|
Health Status | 5 | 2012 | 399 | 0.250 |
Why?
|
Age Factors | 7 | 2018 | 1187 | 0.250 |
Why?
|
Body Weight | 5 | 2013 | 310 | 0.240 |
Why?
|
Cross-Sectional Studies | 10 | 2020 | 1532 | 0.240 |
Why?
|
Anthropometry | 3 | 2013 | 83 | 0.240 |
Why?
|
Magnetic Resonance Imaging | 7 | 2019 | 1328 | 0.230 |
Why?
|
Ultrafiltration | 2 | 2016 | 9 | 0.230 |
Why?
|
Hyperphosphatemia | 3 | 2011 | 6 | 0.220 |
Why?
|
Interleukin-18 | 2 | 2020 | 9 | 0.220 |
Why?
|
Hematocrit | 2 | 2002 | 23 | 0.210 |
Why?
|
Drug Prescriptions | 1 | 2003 | 54 | 0.210 |
Why?
|
Dialysis | 1 | 2002 | 3 | 0.210 |
Why?
|
Dietary Proteins | 4 | 2011 | 55 | 0.210 |
Why?
|
Risk | 5 | 2019 | 320 | 0.210 |
Why?
|
Fee-for-Service Plans | 1 | 2002 | 12 | 0.200 |
Why?
|
Blood Volume | 1 | 2002 | 8 | 0.200 |
Why?
|
Sex Factors | 5 | 2018 | 661 | 0.200 |
Why?
|
Nutrition Surveys | 2 | 2022 | 148 | 0.200 |
Why?
|
Dietary Supplements | 2 | 2014 | 185 | 0.190 |
Why?
|
Hemodiafiltration | 2 | 2013 | 2 | 0.190 |
Why?
|
Physical Fitness | 2 | 2012 | 131 | 0.180 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2021 | 170 | 0.180 |
Why?
|
Multivariate Analysis | 8 | 2017 | 683 | 0.180 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2018 | 135 | 0.180 |
Why?
|
Education | 1 | 2020 | 38 | 0.180 |
Why?
|
Tissue Inhibitor of Metalloproteinase-2 | 1 | 2019 | 1 | 0.180 |
Why?
|
Communication Barriers | 1 | 2020 | 22 | 0.180 |
Why?
|
Hispanic Americans | 3 | 2016 | 940 | 0.170 |
Why?
|
Diuretics | 1 | 2019 | 26 | 0.170 |
Why?
|
Myocardial Infarction | 2 | 2022 | 475 | 0.170 |
Why?
|
Chemokine CCL2 | 1 | 2020 | 48 | 0.170 |
Why?
|
Biopsy | 2 | 2018 | 259 | 0.170 |
Why?
|
Drug Administration Schedule | 2 | 2017 | 276 | 0.170 |
Why?
|
Drinking | 1 | 2019 | 10 | 0.170 |
Why?
|
Water Supply | 1 | 2019 | 10 | 0.170 |
Why?
|
Home Care Services | 1 | 2020 | 51 | 0.170 |
Why?
|
International Cooperation | 1 | 2019 | 28 | 0.170 |
Why?
|
Tissue and Organ Procurement | 1 | 2020 | 93 | 0.170 |
Why?
|
Health Services Needs and Demand | 1 | 2020 | 81 | 0.170 |
Why?
|
Cost-Benefit Analysis | 2 | 2010 | 185 | 0.170 |
Why?
|
Diabetes Complications | 1 | 2020 | 177 | 0.170 |
Why?
|
Caregivers | 1 | 2020 | 114 | 0.160 |
Why?
|
Nutrition Assessment | 2 | 2011 | 55 | 0.160 |
Why?
|
Congresses as Topic | 1 | 2018 | 41 | 0.160 |
Why?
|
Evidence-Based Medicine | 3 | 2018 | 217 | 0.160 |
Why?
|
Prognosis | 8 | 2020 | 1495 | 0.160 |
Why?
|
European Continental Ancestry Group | 6 | 2016 | 1166 | 0.160 |
Why?
|
Incidence | 5 | 2021 | 1196 | 0.160 |
Why?
|
Longitudinal Studies | 5 | 2019 | 766 | 0.160 |
Why?
|
Hemoglobins | 3 | 2016 | 49 | 0.160 |
Why?
|
Body Mass Index | 6 | 2013 | 922 | 0.150 |
Why?
|
Survival Rate | 5 | 2020 | 877 | 0.150 |
Why?
|
Reference Standards | 1 | 2017 | 32 | 0.150 |
Why?
|
Multiple Sclerosis | 1 | 2018 | 59 | 0.150 |
Why?
|
Cardiology | 1 | 2019 | 99 | 0.150 |
Why?
|
Predictive Value of Tests | 6 | 2020 | 873 | 0.150 |
Why?
|
Sodium Potassium Chloride Symporter Inhibitors | 2 | 2014 | 12 | 0.150 |
Why?
|
Thyroid Function Tests | 1 | 2017 | 4 | 0.150 |
Why?
|
Hypothyroidism | 1 | 2017 | 12 | 0.140 |
Why?
|
Thyroid Gland | 1 | 2017 | 15 | 0.140 |
Why?
|
Hyperprolactinemia | 1 | 2016 | 2 | 0.140 |
Why?
|
Ventricular Function, Left | 2 | 2021 | 245 | 0.140 |
Why?
|
Renin-Angiotensin System | 1 | 2018 | 179 | 0.140 |
Why?
|
Hemorrhage | 1 | 2017 | 100 | 0.140 |
Why?
|
Cognition | 3 | 2016 | 555 | 0.140 |
Why?
|
Critical Care | 1 | 2017 | 107 | 0.140 |
Why?
|
Dementia | 1 | 2019 | 252 | 0.130 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2017 | 632 | 0.130 |
Why?
|
Young Adult | 4 | 2020 | 2635 | 0.130 |
Why?
|
Regression Analysis | 5 | 2019 | 293 | 0.130 |
Why?
|
Prevalence | 4 | 2013 | 981 | 0.130 |
Why?
|
Chi-Square Distribution | 5 | 2017 | 297 | 0.130 |
Why?
|
Catheterization | 2 | 2013 | 58 | 0.130 |
Why?
|
Intention to Treat Analysis | 1 | 2015 | 28 | 0.130 |
Why?
|
Malnutrition | 2 | 2005 | 17 | 0.120 |
Why?
|
Comorbidity | 5 | 2017 | 564 | 0.120 |
Why?
|
Stroke | 2 | 2017 | 584 | 0.120 |
Why?
|
Weight Gain | 2 | 2016 | 117 | 0.120 |
Why?
|
Patient Acceptance of Health Care | 2 | 2010 | 171 | 0.120 |
Why?
|
Heart Diseases | 2 | 2007 | 116 | 0.120 |
Why?
|
National Health Programs | 1 | 2014 | 4 | 0.120 |
Why?
|
Brain | 2 | 2019 | 951 | 0.120 |
Why?
|
Genetic Variation | 2 | 2014 | 244 | 0.120 |
Why?
|
Bone Density Conservation Agents | 1 | 2014 | 23 | 0.120 |
Why?
|
Renal Circulation | 1 | 2014 | 13 | 0.120 |
Why?
|
Organ Size | 2 | 2019 | 218 | 0.120 |
Why?
|
Furosemide | 1 | 2014 | 9 | 0.120 |
Why?
|
Renal Artery | 1 | 2014 | 47 | 0.110 |
Why?
|
Autoantigens | 1 | 2013 | 16 | 0.110 |
Why?
|
Glomerulosclerosis, Focal Segmental | 2 | 2011 | 38 | 0.110 |
Why?
|
Renal Artery Obstruction | 1 | 2014 | 41 | 0.110 |
Why?
|
Hypertrophy, Right Ventricular | 1 | 2013 | 6 | 0.110 |
Why?
|
Glomerulonephritis | 1 | 2013 | 21 | 0.110 |
Why?
|
Ventricular Function, Right | 1 | 2013 | 17 | 0.110 |
Why?
|
Erythropoietin | 3 | 2003 | 30 | 0.110 |
Why?
|
Membranes, Artificial | 2 | 2003 | 7 | 0.110 |
Why?
|
Patient Care Planning | 1 | 2014 | 58 | 0.110 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2013 | 73 | 0.110 |
Why?
|
Atrial Fibrillation | 1 | 2017 | 320 | 0.110 |
Why?
|
Ventricular Remodeling | 1 | 2013 | 58 | 0.110 |
Why?
|
JC Virus | 1 | 2013 | 20 | 0.110 |
Why?
|
Body Composition | 4 | 2011 | 397 | 0.110 |
Why?
|
Tumor Virus Infections | 1 | 2013 | 21 | 0.110 |
Why?
|
Polyomavirus Infections | 1 | 2013 | 21 | 0.110 |
Why?
|
Reproducibility of Results | 2 | 2008 | 762 | 0.110 |
Why?
|
Oxygen | 1 | 2014 | 142 | 0.110 |
Why?
|
Odds Ratio | 3 | 2007 | 472 | 0.110 |
Why?
|
African Continental Ancestry Group | 2 | 2012 | 363 | 0.110 |
Why?
|
Neoplasm Proteins | 1 | 2013 | 148 | 0.110 |
Why?
|
Insurance Coverage | 1 | 2013 | 75 | 0.100 |
Why?
|
Research Design | 3 | 2019 | 313 | 0.100 |
Why?
|
Socioeconomic Factors | 2 | 2011 | 422 | 0.100 |
Why?
|
Eating | 2 | 2003 | 74 | 0.100 |
Why?
|
Ethnic Groups | 2 | 2013 | 476 | 0.100 |
Why?
|
Membrane Proteins | 1 | 2013 | 256 | 0.100 |
Why?
|
Attitude of Health Personnel | 1 | 2013 | 183 | 0.100 |
Why?
|
Sensitivity and Specificity | 2 | 2018 | 582 | 0.100 |
Why?
|
North America | 1 | 2011 | 32 | 0.100 |
Why?
|
Geography | 2 | 2009 | 34 | 0.100 |
Why?
|
Activities of Daily Living | 2 | 2011 | 257 | 0.100 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2013 | 1062 | 0.090 |
Why?
|
Product Recalls and Withdrawals | 1 | 2010 | 1 | 0.090 |
Why?
|
Equipment Design | 1 | 2011 | 171 | 0.090 |
Why?
|
Folic Acid | 1 | 2010 | 12 | 0.090 |
Why?
|
Homocysteine | 1 | 2010 | 14 | 0.090 |
Why?
|
Urinalysis | 2 | 2021 | 27 | 0.090 |
Why?
|
Drug Costs | 1 | 2010 | 47 | 0.090 |
Why?
|
Retrospective Studies | 7 | 2009 | 3502 | 0.090 |
Why?
|
Abdominal Fat | 1 | 2010 | 50 | 0.090 |
Why?
|
Molecular Motor Proteins | 1 | 2010 | 58 | 0.090 |
Why?
|
Myosin Heavy Chains | 1 | 2010 | 89 | 0.090 |
Why?
|
Graft Rejection | 1 | 2011 | 238 | 0.090 |
Why?
|
Logistic Models | 3 | 2016 | 778 | 0.090 |
Why?
|
Heart Ventricles | 1 | 2010 | 135 | 0.090 |
Why?
|
Administration, Oral | 3 | 2017 | 187 | 0.090 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 2 | 2020 | 28 | 0.090 |
Why?
|
Water-Electrolyte Balance | 2 | 2016 | 16 | 0.080 |
Why?
|
Heart Failure, Diastolic | 1 | 2009 | 15 | 0.080 |
Why?
|
Life Style | 1 | 2011 | 408 | 0.080 |
Why?
|
Genetic Predisposition to Disease | 4 | 2013 | 835 | 0.080 |
Why?
|
Uremia | 2 | 2007 | 9 | 0.080 |
Why?
|
Patient Selection | 1 | 2010 | 276 | 0.080 |
Why?
|
Mexican Americans | 1 | 2009 | 60 | 0.080 |
Why?
|
Ticlopidine | 1 | 2008 | 17 | 0.080 |
Why?
|
Graft Occlusion, Vascular | 1 | 2008 | 24 | 0.080 |
Why?
|
Demography | 2 | 2005 | 109 | 0.080 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2008 | 83 | 0.080 |
Why?
|
Disability Evaluation | 1 | 2009 | 240 | 0.080 |
Why?
|
Thrombosis | 1 | 2008 | 73 | 0.070 |
Why?
|
Referral and Consultation | 1 | 2009 | 141 | 0.070 |
Why?
|
Models, Biological | 1 | 2010 | 392 | 0.070 |
Why?
|
Appointments and Schedules | 1 | 2007 | 22 | 0.070 |
Why?
|
Adipose Tissue | 1 | 2010 | 349 | 0.070 |
Why?
|
Random Allocation | 3 | 2003 | 226 | 0.070 |
Why?
|
Energy Metabolism | 1 | 2008 | 147 | 0.070 |
Why?
|
Chronic Disease | 1 | 2009 | 405 | 0.070 |
Why?
|
Genotype | 3 | 2016 | 733 | 0.070 |
Why?
|
Recombinant Proteins | 3 | 2003 | 247 | 0.070 |
Why?
|
Delivery of Health Care | 1 | 2009 | 160 | 0.070 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2009 | 145 | 0.070 |
Why?
|
Metabolic Clearance Rate | 2 | 2003 | 17 | 0.070 |
Why?
|
Linear Models | 3 | 2013 | 447 | 0.070 |
Why?
|
C-Reactive Protein | 1 | 2007 | 238 | 0.070 |
Why?
|
Feasibility Studies | 2 | 2021 | 293 | 0.070 |
Why?
|
Medicaid | 2 | 2003 | 94 | 0.070 |
Why?
|
Data Interpretation, Statistical | 2 | 2006 | 109 | 0.060 |
Why?
|
Liver | 1 | 2008 | 484 | 0.060 |
Why?
|
Stroke Volume | 2 | 2021 | 348 | 0.060 |
Why?
|
Dialysis Solutions | 2 | 2016 | 6 | 0.060 |
Why?
|
Multicenter Studies as Topic | 3 | 2010 | 105 | 0.060 |
Why?
|
Diabetic Foot | 1 | 2004 | 19 | 0.060 |
Why?
|
Diet Records | 1 | 2004 | 33 | 0.060 |
Why?
|
Amputation | 1 | 2004 | 38 | 0.060 |
Why?
|
Leg | 1 | 2004 | 65 | 0.060 |
Why?
|
Health Surveys | 2 | 2002 | 196 | 0.060 |
Why?
|
Indians, North American | 1 | 2004 | 109 | 0.060 |
Why?
|
Confidence Intervals | 2 | 2018 | 149 | 0.060 |
Why?
|
Decision Support Techniques | 1 | 2004 | 128 | 0.060 |
Why?
|
Asian Continental Ancestry Group | 1 | 2003 | 108 | 0.060 |
Why?
|
Gene Frequency | 2 | 2013 | 220 | 0.050 |
Why?
|
Health Maintenance Organizations | 1 | 2002 | 13 | 0.050 |
Why?
|
Death Certificates | 1 | 2002 | 5 | 0.050 |
Why?
|
Feeding Behavior | 1 | 2003 | 161 | 0.050 |
Why?
|
Autopsy | 1 | 2002 | 35 | 0.050 |
Why?
|
Blood Vessel Prosthesis | 1 | 2002 | 83 | 0.050 |
Why?
|
Hypertension, Renal | 1 | 2002 | 29 | 0.050 |
Why?
|
Health Services | 1 | 2002 | 38 | 0.050 |
Why?
|
Costs and Cost Analysis | 1 | 2002 | 99 | 0.050 |
Why?
|
Nutrition Disorders | 1 | 2001 | 12 | 0.050 |
Why?
|
Quality Indicators, Health Care | 1 | 2001 | 59 | 0.050 |
Why?
|
Canada | 2 | 2012 | 56 | 0.050 |
Why?
|
Bolivia | 1 | 2021 | 2 | 0.050 |
Why?
|
Nepal | 1 | 2021 | 9 | 0.050 |
Why?
|
Malawi | 1 | 2021 | 19 | 0.050 |
Why?
|
Terminology as Topic | 2 | 2013 | 64 | 0.050 |
Why?
|
Diabetes Mellitus | 1 | 2004 | 411 | 0.050 |
Why?
|
International Agencies | 1 | 2020 | 10 | 0.050 |
Why?
|
Phenotype | 2 | 2013 | 632 | 0.050 |
Why?
|
Clinical Protocols | 2 | 2014 | 98 | 0.050 |
Why?
|
Iron | 1 | 2001 | 116 | 0.050 |
Why?
|
Developing Countries | 1 | 2021 | 48 | 0.050 |
Why?
|
Patient Readmission | 1 | 2021 | 125 | 0.050 |
Why?
|
Internationality | 1 | 2020 | 22 | 0.040 |
Why?
|
Matrix Metalloproteinases | 1 | 2019 | 11 | 0.040 |
Why?
|
Medication Adherence | 1 | 2022 | 161 | 0.040 |
Why?
|
Dehydration | 1 | 2019 | 8 | 0.040 |
Why?
|
Alpha-Globulins | 1 | 2019 | 1 | 0.040 |
Why?
|
Patient Participation | 1 | 2020 | 82 | 0.040 |
Why?
|
Single-Blind Method | 1 | 2019 | 203 | 0.040 |
Why?
|
Mexico | 1 | 2019 | 71 | 0.040 |
Why?
|
Diarrhea | 1 | 2019 | 60 | 0.040 |
Why?
|
Community Health Services | 1 | 2019 | 56 | 0.040 |
Why?
|
Acute Disease | 1 | 2019 | 252 | 0.040 |
Why?
|
American Heart Association | 1 | 2019 | 87 | 0.040 |
Why?
|
Multiple Organ Failure | 1 | 2008 | 10 | 0.040 |
Why?
|
Remission Induction | 1 | 2018 | 84 | 0.040 |
Why?
|
Pyridones | 1 | 2017 | 10 | 0.040 |
Why?
|
Thiazoles | 1 | 2017 | 27 | 0.040 |
Why?
|
North Carolina | 2 | 2013 | 1514 | 0.040 |
Why?
|
Warfarin | 1 | 2017 | 29 | 0.040 |
Why?
|
Pyridines | 1 | 2017 | 76 | 0.040 |
Why?
|
Critical Illness | 1 | 2008 | 87 | 0.040 |
Why?
|
Infant | 1 | 2021 | 1059 | 0.040 |
Why?
|
Pyrazoles | 1 | 2017 | 67 | 0.040 |
Why?
|
Puerto Rico | 1 | 2016 | 11 | 0.040 |
Why?
|
Child, Preschool | 1 | 2021 | 1268 | 0.040 |
Why?
|
Phosphorus | 1 | 2016 | 10 | 0.030 |
Why?
|
Verbal Learning | 1 | 2016 | 8 | 0.030 |
Why?
|
Executive Function | 1 | 2016 | 57 | 0.030 |
Why?
|
Goals | 1 | 2015 | 36 | 0.030 |
Why?
|
Attention | 1 | 2016 | 83 | 0.030 |
Why?
|
Reaction Time | 1 | 2016 | 117 | 0.030 |
Why?
|
Psychomotor Performance | 1 | 2016 | 99 | 0.030 |
Why?
|
Acute Coronary Syndrome | 1 | 2017 | 196 | 0.030 |
Why?
|
Sodium Chloride Symporter Inhibitors | 1 | 2014 | 10 | 0.030 |
Why?
|
Neuropsychological Tests | 1 | 2016 | 371 | 0.030 |
Why?
|
Calcium Channel Blockers | 1 | 2014 | 48 | 0.030 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2014 | 61 | 0.030 |
Why?
|
Child | 1 | 2021 | 2436 | 0.030 |
Why?
|
Memory | 1 | 2016 | 190 | 0.030 |
Why?
|
Data Collection | 1 | 2014 | 180 | 0.030 |
Why?
|
Bone Morphogenetic Protein 4 | 1 | 2013 | 13 | 0.030 |
Why?
|
Epistasis, Genetic | 1 | 2013 | 44 | 0.030 |
Why?
|
Skinfold Thickness | 1 | 2013 | 7 | 0.030 |
Why?
|
Genetic Association Studies | 1 | 2013 | 146 | 0.030 |
Why?
|
Nonlinear Dynamics | 1 | 2013 | 51 | 0.030 |
Why?
|
Blood Urea Nitrogen | 1 | 2013 | 12 | 0.030 |
Why?
|
Buffers | 1 | 2013 | 9 | 0.030 |
Why?
|
DNA, Viral | 1 | 2013 | 54 | 0.030 |
Why?
|
Urodynamics | 1 | 2013 | 37 | 0.030 |
Why?
|
Water | 1 | 2013 | 56 | 0.030 |
Why?
|
Health Care Surveys | 1 | 2013 | 185 | 0.030 |
Why?
|
Heredity | 1 | 2012 | 13 | 0.030 |
Why?
|
Pedigree | 1 | 2012 | 140 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2013 | 893 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2011 | 198 | 0.020 |
Why?
|
Electric Impedance | 1 | 2011 | 13 | 0.020 |
Why?
|
HLA Antigens | 1 | 2011 | 40 | 0.020 |
Why?
|
Transplantation, Homologous | 1 | 2011 | 151 | 0.020 |
Why?
|
Exercise Test | 1 | 2012 | 227 | 0.020 |
Why?
|
Homozygote | 1 | 2010 | 58 | 0.020 |
Why?
|
Vitamin B 6 | 1 | 2010 | 2 | 0.020 |
Why?
|
Vitamin B 12 | 1 | 2010 | 8 | 0.020 |
Why?
|
Hyperhomocysteinemia | 1 | 2010 | 5 | 0.020 |
Why?
|
Proteinuria | 1 | 2010 | 59 | 0.020 |
Why?
|
Family Health | 1 | 2010 | 76 | 0.020 |
Why?
|
Fear | 1 | 2010 | 48 | 0.020 |
Why?
|
Educational Status | 1 | 2010 | 179 | 0.020 |
Why?
|
Housing | 1 | 2010 | 65 | 0.020 |
Why?
|
Tissue Donors | 1 | 2011 | 198 | 0.020 |
Why?
|
Perception | 1 | 2010 | 98 | 0.020 |
Why?
|
Graft Survival | 1 | 2011 | 313 | 0.020 |
Why?
|
Motivation | 1 | 2010 | 112 | 0.020 |
Why?
|
Immunosuppressive Agents | 1 | 2011 | 240 | 0.020 |
Why?
|
Waiting Lists | 1 | 2009 | 34 | 0.020 |
Why?
|
Self Care | 1 | 2010 | 144 | 0.020 |
Why?
|
Hand Strength | 1 | 2009 | 101 | 0.020 |
Why?
|
Blood Glucose | 1 | 2011 | 494 | 0.020 |
Why?
|
Transplants | 1 | 2008 | 23 | 0.020 |
Why?
|
Vascular Patency | 1 | 2008 | 69 | 0.020 |
Why?
|
Reference Values | 1 | 2008 | 245 | 0.020 |
Why?
|
Protein-Energy Malnutrition | 1 | 2007 | 4 | 0.020 |
Why?
|
Walking | 1 | 2009 | 209 | 0.020 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2016 | 1428 | 0.020 |
Why?
|
Depression | 1 | 2010 | 444 | 0.020 |
Why?
|
Treatment Refusal | 1 | 2006 | 11 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2008 | 525 | 0.020 |
Why?
|
Healthcare Disparities | 1 | 2008 | 166 | 0.020 |
Why?
|
Circadian Rhythm | 1 | 2006 | 43 | 0.020 |
Why?
|
Cholesterol | 1 | 2005 | 252 | 0.010 |
Why?
|
Inflammation | 1 | 2007 | 530 | 0.010 |
Why?
|
Myocardial Ischemia | 1 | 2004 | 107 | 0.010 |
Why?
|
Length of Stay | 1 | 2004 | 314 | 0.010 |
Why?
|
Injections, Subcutaneous | 1 | 2002 | 35 | 0.010 |
Why?
|
Injections, Intravenous | 1 | 2002 | 78 | 0.010 |
Why?
|
Mental Health | 1 | 2002 | 117 | 0.010 |
Why?
|
Proteins | 1 | 2002 | 144 | 0.010 |
Why?
|